• Explore /
  • Poster
  • / Expert consensus recommendations for managing hyperglycemia and rash in patients with <em>PIK3CA</em>-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Abstract Video & Slides Poster

Authors

null

Emily J. Gallagher

Icahn School of Medicine at Mount Sinai Hospital, New York, NY

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science

Sub Track

Tools for Management of Treatment and Adverse Effects

Citation

J Clin Oncol 40, 2022 (suppl 28; abstr 422)

DOI

10.1200/JCO.2022.40.28_suppl.422

Abstract #

422

Poster Bd #

F25

Abstract Disclosures

Similar Posters

First Author: Dejan Juric

First Author: Dejan Juric

First Author: Stephen K. L. Chia

First Author: Peter Cornelius